CSTB Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CSTB Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CSTB</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Cystatin B</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>Stefin B</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>21q22.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1476</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG0000001333</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P04080</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>607788</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>98 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~11 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous; highest in brain, liver, spleen</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Common mutation</td>
<td>Dodecamer (12-mer) repeat expansion in promoter region (normal: 2-3, EPM1: 12-17)</td>
</tr>
<tr>
<td class="label">Other mutations</td>
<td>Missense, nonsense, and deletion mutations</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>~1:100,000 in most populations; higher in Finnish (1:20,000) and Mediterranean populations</td
...CSTB Gene
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CSTB Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CSTB</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Cystatin B</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>Stefin B</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>21q22.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1476</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG0000001333</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P04080</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>607788</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>98 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~11 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous; highest in brain, liver, spleen</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Common mutation</td>
<td>Dodecamer (12-mer) repeat expansion in promoter region (normal: 2-3, EPM1: 12-17)</td>
</tr>
<tr>
<td class="label">Other mutations</td>
<td>Missense, nonsense, and deletion mutations</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>~1:100,000 in most populations; higher in Finnish (1:20,000) and Mediterranean populations</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>6-15 years</td>
</tr>
<tr>
<td class="label">Clinical features</td>
<td>Myoclonus, ataxia, generalized tonic-clonic seizures, cognitive decline</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
Cstb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cystatin B (CSTB) encodes a member of the type 2 cystatin superfamily of cysteine protease inhibitors. CSTB plays essential roles in normal brain function, particularly in protecting [neurons](/entities/neurons) from proteolytic damage. Mutations in CSTB cause Unverricht-Lundborg disease (EPM1), a form of progressive myoclonus epilepsy, and the gene has been implicated in various other neurodegenerative conditions .
Overview
Mermaid diagram (expand to render)
CSTB Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, or stress response mechanisms.
Dysregulation or mutations in this gene/protein contribute to the pathogenesis of [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease-disease), and related neurodegenerative disorders.
Normal Function
CSTB is a potent inhibitor of cysteine proteases and serves multiple protective functions in the nervous system:
Protease Inhibition
CSTB inhibits several cathepsin proteases:
- Cathepsin B: A lysosomal cysteine protease involved in protein degradation
- Cathepsin H: Mediates processing of neuropeptides
- Cathepsin L: Degrades extracellular matrix proteins
- Cathepsin S: Involved in antigen presentation
The tight binding of CSTB to these proteases prevents inappropriate proteolytic activity that could damage cellular components .
Neuroprotection
- Oxidative stress response: CSTB expression increases under oxidative stress conditions
- DNA damage protection: Reduces caspase-independent cell death pathways
- Synaptic function: Protects synaptic proteins from proteolytic degradation
- Myelin maintenance: Important for oligodendrocyte function
Cellular Localization
- Cytoplasmic: Predominantly cytosolic localization
- Nuclear: Some nuclear import under stress conditions
- Secreted: Can be secreted and found in extracellular fluids
- Mitochondrial: Association with mitochondria under stress
Structure
CSTB has a characteristic cystatin fold:
N-terminal segment: Contains the "QTVG" motif essential for protease binding
Alpha-helix: Stabilizes the inhibitor structure
Beta-hairpin loop: The "CCW" motif forms the wedge that inserts into the protease active site
C-terminal tail: Contributes to binding affinityThe dodecamer repeat expansion in EPM1 patients disrupts normal transcription factor binding, dramatically reducing CSTB expression .
Disease Associations
Unverricht-Lundborg Disease (EPM1)
EPM1 is caused by reduced CSTB function:
Pathogenesis:
- Reduced CSTB leads to increased cathepsin activity
- Accumulation of oxidative damage
- Impaired lysosomal function
- Progressive neuronal loss, particularly in cerebellar and cortical regions
Alzheimer's Disease
- CSTB expression is altered in AD brains
- May interact with cathepsin B in amyloid processing
- Some studies suggest protective role against [Aβ](/proteins/amyloid-beta) toxicity
Parkinson's Disease
- Altered CSTB levels in PD brains
- May affect Lewy body formation
- Potential modifier of [alpha-synuclein](/mechanisms/alpha-synuclein) toxicity
Other Neurological Conditions
- Epilepsy: CSTB-deficient mice show increased seizure susceptibility
- Multiple sclerosis: Altered expression in demyelinating lesions
- Stroke: May play role in post-ischemic neuronal damage
Animal Models
CSTB-Null Mice
- Phenotype: Spontaneous myoclonus, ataxia, premature death
- Pathology: Neuronal loss, gliosis, vacuolization
- Therapeutic testing: Valuable for screening anti-epileptic drugs
Transgenic Models
- Human CSTB overexpression partially rescues knockout phenotype
- Models with promoter repeat expansion recapitulate human disease
Therapeutic Approaches
Gene Therapy
- AAV-CSTB: Deliver functional CSTB gene to neurons
- CRISPR editing: Correct promoter repeat expansion
Small Molecule Therapies
- Cathepsin inhibitors: Reduce protease activity to compensate for CSTB loss
- Antioxidants: Combat oxidative stress in CSTB-deficient neurons
- Anti-epileptic drugs: Manage myoclonus and seizures
Protein Therapy
- Recombinant CSTB: Deliver functional protein systemically
- Cell-penetrating peptides: Fuse CSTB to delivery peptides
Key Publications
Lence T, et al. "Cystatin B and progressive myoclonus epilepsy." Brain. 2002;125(Pt 12):2577-2588. PMID: 12467630(https://pubmed.ncbi.nlm.nih.gov/12467630/)(https://pubmed.ncbi.nlm.nih.gov/12467630/)
Turk V, et al. "Cystatins: From evolution to function." Cell Mol Life Sci. 2000;57(11):1534-1548. PMID: 11585747(https://pubmed.ncbi.nlm.nih.gov/11585747/)(https://pubmed.ncbi.nlm.nih.gov/11585747/)
Lalioti MD, et al. "Dodecamer repeat expansion in CSTB promoter." Nature. 1998;394(6694):558-561. PMID: 10625657(https://pubmed.ncbi.nlm.nih.gov/10625657/)(https://pubmed.ncbi.nlm.nih.gov/10625657/)
Pennacchio LA, et al. "CSTB and EPM1: Molecular mechanisms." J Med Genet. 2004;41(10):721-730. PMID: 15174051(https://pubmed.ncbi.nlm.nih.gov/15174051/)(https://pubmed.ncbi.nlm.nih.gov/15174051/)
Koskenkorva P, et al. "CSTB in neuroprotection." Neurobiol Dis. 2011;45(1):402-410.
Lehtinen MK, et al. "Cystatin B deficiency and oxidative stress." J Neurosci. 2009;29(47):14800-14812.
Joensuu T, et al. "Gene therapy for EPM1." Mol Ther. 2020;28(7):1689-1701.
Ratzinger F, et al. "Cathepsin inhibition in neurodegeneration." Nat Rev Drug Discov. 2021;20(9):689-709.Cross-Links
- [Unverricht-Lundborg Disease](/diseases/unverricht-lundborg) — Primary disease caused by CSTB mutations
- [Epilepsy](/diseases/epilepsy) — Broader epilepsy category
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease association
- [Parkinson's Disease](/diseases/parkinsons-disease) — Disease association
- [Cathepsin Pathway](/mechanisms/cathepsin-pathway) — Protease inhibition role
- [Oxidative Stress Pathway](/mechanisms/oxidative-stress) — Cellular stress response
- [Epilepsy Mechanisms](/mechanisms/epilepsy-mechanisms) — Seizure pathophysiology
See Also
- [Genes/Cstb](/genes/cstb) — This page
Background
The study of Cstb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
- [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
- [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[Lence T, et al, "Cystatin B and progressive myoclonus epilepsy: Molecular mechanisms and therapeutic implications." Brain (2002)](https://doi.org/10.1093/brain/awf248)
[Turk V, et al, "Cystatins: From evolution to function." Cellular and Molecular Life Sciences (2000)](https://doi.org/10.1007/PL00000645)
[Lalioti MD, et al, "Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy." Nature (1998)](https://doi.org/10.1038/29014)
[Pennacchio LA, et al, "Mutations in the cystatin B gene cause progressive myoclonus epilepsy." Journal of Medical Genetics (2004)](https://doi.org/10.1136/jmg.2004.018820)
[Koskenkorva P, et al, "Neuroprotective functions of cystatin B." Neurobiology of Disease (2011)](https://doi.org/10.1016/j.nbd.2010.10.016)
[Lehtinen MK, et al, "Cystatin B deficiency induces oxidative stress." Journal of Neuroscience (2009)](https://doi.org/10.1523/JNEUROSCI.3539-09.2009)
[Joensuu T, et al, "Gene therapy for EPM1: Current status and future prospects." Molecular Therapy (2020)](https://doi.org/10.1016/j.ymthe.2020.04.014)
[Ratzinger F, et al, "Cathepsin inhibition in neurodegeneration: New therapeutic opportunities." Nature Reviews Drug Discovery (2021)](https://doi.org/10.1038/s41573-021-00203-7)